Data gathered: July 13
Alternative Data for Black Diamond Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 76 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| Patents | 5 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 23 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,661 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 26 | Sign up | Sign up | Sign up |
| Linkedin Employees | 36 | Sign up | Sign up | Sign up |
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers.
| Price | $2.87 |
| Target Price | Sign up |
| Volume | 1,010,000 |
| Market Cap | $163M |
| Year Range | $1.25 - $3.38 |
| Dividend Yield | 0% |
| PE Ratio | 47.83 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Recommendation of “Buy” from AnalystsJuly 10 - ETF Daily News |
 |
Raymond James Financial Initiates Coverage on Black Diamond Therapeutics (NASDAQ:BDTX)July 2 - ETF Daily News |
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) dropped from Russell 3000 IndexJune 30 - Finnhub |
|
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) dropped from Russell 2000 IndexJune 30 - Finnhub |
|
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) dropped from Russell 2000 Dynamic IndexJune 30 - Finnhub |
|
Black Diamond Therapeutics, Inc.(NasdaqGS: BDTX) dropped from Russell 3000E Growth IndexJune 29 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 70M | 0 | 0 | 57M | 55M | 0.980 |
| Q4 '24 | 0 | 0 | 0 | -16M | -18M | -0.280 |
| Q3 '24 | 0 | 86,000 | -86,000 | -16M | -18M | -0.275 |
| Q2 '24 | 0 | 86,000 | -86,000 | -20M | -22M | -0.360 |
| Q1 '24 | 0 | 86,000 | -86,000 | -18M | -20M | -0.350 |
Insider Transactions View All
| BB BIOTECH AG filed to sell 7,217,839 shares at $1.9. March 20 '25 |
| BB BIOTECH AG filed to sell 3,817,839 shares at $2.1. March 20 '25 |
| BB BIOTECH AG filed to sell 2,733,547 shares at $2.1. March 20 '25 |
| BB BIOTECH AG filed to sell 3,233,547 shares at $2. March 20 '25 |
| BB BIOTECH AG filed to sell 6,217,839 shares at $2.3. March 20 '25 |
Similar companies
Read more about Black Diamond Therapeutics (BDTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Black Diamond Therapeutics?
The Market Cap of Black Diamond Therapeutics is $163M.
What is Black Diamond Therapeutics' PE Ratio?
As of today, Black Diamond Therapeutics' PE (Price to Earnings) ratio is 47.83.
What is the current stock price of Black Diamond Therapeutics?
Currently, the price of one share of Black Diamond Therapeutics stock is $2.87.
How can I analyze the BDTX stock price chart for investment decisions?
The BDTX stock price chart above provides a comprehensive visual representation of Black Diamond Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Black Diamond Therapeutics shares. Our platform offers an up-to-date BDTX stock price chart, along with technical data analysis and alternative data insights.
Does BDTX offer dividends to its shareholders?
As of our latest update, Black Diamond Therapeutics (BDTX) does not offer dividends to its shareholders. Investors interested in Black Diamond Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Black Diamond Therapeutics?
Some of the similar stocks of Black Diamond Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.